Expression of CD147 in advanced non-small cell lung cancer correlated with cisplatin-based chemotherapy resistance

Abstract

CD147, a widely expressed cell surface glycoprotein in cancer, is associated with tumor invasiveness and chemotherapy resistance. Recently, CD147 is also regarded as a potential therapeutic target for cancer therapy. The aim of the study was to investigate CD147 expression in non-small cell lung cancer (NSCLC), and evaluate its correlation with cisplatin-based chemotherapy resistance. In this study, we examined immunohistochemically the expression of CD147 in 118 advanced NSCLC cases treated with cisplatin-based chemotherapy, and then the association of CD147 expression with clinicopathological characteristics was analyzed. Furthermore, RNA interference approach was used to silence CD147 expression in a cisplatin-resistant human lung cancer cell line A549/DDP, and the inhibition effect of cisplatin on tumor cells was assayed by MTT. In the overall series, positive CD147 expression was observed in 101/118 (85.6%) cases. A membranous CD147 pattern was identified in 76/101 (75.2%) of CD147 positive tumors. CD147 membranous expression,but not the overall CD147 expression, was associated with poor response to cisplatin-based chemotherapies and a poor prognosis in advanced NSCLC patients. In vitro results showed that silencing CD147 increased the proliferation inhibitory effect of cisplatin to A549/DDP cells. In conclusion, our study indicated that membranous CD147 expression is a predictive factor of the response to cisplatin-based chemotherapies, and the use of CD147-targeted therapeutic adjuvants might be considered in the treatment of advanced NSCLC patients.

Overexpression of CD147 contributes to the chemoresistance of head and neck squamous cell carcinoma cells

“…In addition to inducing MMPs production, CD147 was shown to interact with integrins and CD147 participated in multiple cellular processes through integrin, such as modulating cell adhesion, invasion and angiogenesis . It was reported that membranous CD147 expression was a predictive factor of poor response to cisplatin‐based chemotherapies, and the use of CD147‐targeted therapeutic adjuvants might be considered in the treatment of patients with advanced in non‐small cell lung cancer and bladder cancer . Our study has proved that CD147 may represent an attractive target for immunotherapeutic approach in patients with tongue squamous cell carcinoma .…”

CD147-CD98hc Complex Contributes to Poor Prognosis of Non-Small Cell Lung Cancer Patients Through Promoting Cell Proliferation Via the PI3K/Akt Signaling Pathway

“…18,26 Zeng et al have reported that CD147 membranous expression was associated with poor response to cisplatin-based chemotherapies and poor prognosis in advanced NSCLC patients. 27 Sienel et al have demonstrated that membranous localization of CD147 predicted prognosis of patients with operable lung AC. 28 In addition, Kaira et al have demonstrated that the positive CD98hc expression is a significant independent factor to predict poor prognosis in NSCLC patients.…”

The role of EMMPRIN expression in ovarian epithelial carcinomas

“…There was also a decrease of monocarboxylate transporter 1 expression in the invasion and metastasis potential of pancreatic cancer cells, as well as increased chemosensitivity to gemcitabine in Panc-1 cells 47 . Membranous EMMPRIN expression, but not the overall EMMPRIN expression, was associated with poor response to cisplatin-based chemotherapies and a poor prognosis in advanced patients with non-small-cell lung carcinoma 48 . Silencing EMMPRIN increased the proliferation-inhibiting effect of cisplatin to lung cancer A549/DDP, 42 laryngeal carcinoma Hep2, 49 and gastric carcinoma SG7901 50 cells.…”